SESSION 2:
OPENING PLENARY SESSION (Continued)
Moderator: Alex von Gabain (Intercell AG, Vienna, Austria)
11.00-11.30
‘Influenza vaccines: will they be available during the next pandemic?’
Klaus Stohr (WHO, Geneva, Switzerland)
11.30-12.00
‘US Pandemic planning: An update’
Nancy Cox (CDC, Atlanta, Georgia, USA)
12.00-12.30
‘Vaccination for an imminent pandemic: can we get there from here?’
David Fedson (Sergy Haut, France)
12.30-14.00
Lunch, Posters & Exhibits
13.00-14.00
SOLVAY PHARMACEUTICALS LUNCH SESSION
Meet-the-Authors of the Rapid Reference Influenza 2nd Edition
‘The Influenza Paradox’
Bram Palache (Solvay Pharmaceuticals)
‘Ageing and Influenza’
Janet McElhaney (University of British Columbia, Vancouver, Canada and University of Connecticut Health Center Farmington, CT, USA)
‘Designing Influenza Vaccines’
Jan Wilschut (University Medical Centre, Groningen, The Netherlands)
SESSION 3:
BASIC RESEARCH & VIROLOGY
Moderator: John Wood (NIBSC, UK)
14.00-14.30
‘Reverse genetics: basic research and implications for influenza vaccine production’
Yoshihiro Kawaoka (University of Wisconsin-Madison, USA)
14.30-15.00
‘Developing pandemic flu vaccine strains’
Jim Robertson (NIBSC, Potters Bar, UK)
15.00-15.30
‘Cross reactivity of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) influenza vaccine in healthy adults against wild-type H5N1 strains’
Katja Hoschler, Robin Gopal, Maria Zambon (Health Protection Agency, London, UK)
Melanie Saville, Stephanie Pepin (Sanofi Pasteur, Marcy L'etoile, France)
15.30-15.45
‘High yield (hy) reassortant viruses for the influenza vaccine: The Darwinian Approach’
Doris Bucher, Jianhua Le, Barbara Pokorny and Andrew A. Fulvini (New York Medical College, Valhalla, New York, USA)
15.45-16.00
Tea Break, Posters & Exhibits
16.00-16.15
‘Antigenic and genetic drift of swine influenza H3N2 viruses’
J.C. de Jong, D.J. Smith, I. Donatelli, G. Barigazzi, K. van Reeth, G.F. Rimmelzwaan, A.D.M.E. Osterhaus and R.A.M. Fouchier (Erasmus Medical Center, Rotterdam, The Netherlands)
16.15-16.30
‘A new substrate for influenza vaccine development’
V. Yusibov et al. (Fraunhofer USA, Newark, Delaware, USA)
16.30-18.00
SESSION 4:
NOVARTIS VACCINES SATELLITE SYMPOSIUM
‘The Future of Flu Vaccines Part I, MF59-adjuvanted influenza vaccines: protection for vulnerable populations’
Chair's introduction
Professor Karl Nicholson (Leicester, United Kingdom)
Choosing vaccines for vulnerable populations: the elderly challenge
Professor Beatrix Grubeck-Loebenstein (Innsbruck, Austria)
Fluad® and MF59: designed for the vulnerable population
Dr Giuseppe Del Giudice (Siena, Italy)
Strategies for vaccinating against pandemic influenza
Professor Neil Ferguson (London, United Kingdom)
Are MF59-adjuvanted pandemic influenza vaccines suitable for stockpile or pre-vaccination?
Professor Karl Nicholson
Panel discussion
